Burning Rock Biotech Ltd - ADR

NASDAQ:BNR  
12.26
-0.72 (-5.55%)
Earnings Announcements

Burning Rock Biotech Q3 Loss Per Class A & Class B Share RMB 1.64

Published: 11/16/2021 02:21 GMT
Burning Rock Biotech Ltd - ADR (BNR) - Q3 Loss per Class A & Class B Share - Rmb 1.64.
Burning Rock Reports Third Quarter 2021 Financial Results.
Q3 Revenue Rose 2.2 Percent to Rmb 126.6 Million.
Burning Rock Biotech - Expect Our Central-laboratory Testing Volumes and Growth of Our In-hospital Testing Volumes, to Be Significantly Impacted.
Burning Rock Biotech - Expect Our 2021 FY Revenue to Be at Or Around Rmb500 Million, Subject to Future Development of Current Wave of Covid Resurgence.
Revenue is expected to be $20.55 Million
Adjusted EPS is expected to be -$0.24

Next Quarter Revenue Guidance is expected to be $19.61 Million
Next Quarter EPS Guidance is expected to be -$0.24

More details on our Analysts Page.